Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stocks in this Quantisnow insightHealth Care
Historical context for NTLA
Across the 24 sessions after earlier NTLA headlines, the stock closed higher 15 times and lower 9 times, with a median move of 4.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NTLA | SPY |
|---|---|---|---|
| Jun 1, 2026 | Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 | -2.4% | +0.3% |
| May 11, 2026 | Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates | +2.3% | +0.2% |
| May 5, 2026 | Intellia Therapeutics to Participate in Upcoming Investor Conferences | -4.0% | +0.8% |
| May 4, 2026 | Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +4.6% | -0.4% |
| Apr 29, 2026 | Intellia Therapeutics Announces Pricing of Public Offering of Common Stock | -5.7% | -0.0% |
| Apr 28, 2026 | Intellia Announces Proposed Public Offering of Common Stock | +1.2% | -0.5% |
Quantisnow market dataNASDAQ
NTLA
Intellia Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Listed since
- 2016
Get push alerts for NTLA
Full NTLA profile on Quantisnow Follow NTLA and get a push notification the moment its next story breaks.